Z. Paroush, I. Keshet, J. Yisraeli, and H. Cedar, Dynamics of demethylation and activation of the alpha-actin gene in myoblasts, Cell, vol.63, pp.1229-1266, 1990.

S. Kriaucionis and N. Heintz, The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain, Science, vol.324, pp.929-959, 2009.

M. Tahiliani, K. P. Koh, Y. Shen, W. A. Pastor, H. Bandukwala et al., Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1, Science, vol.324, p.9305, 2009.

D. M. Franchini and K. M. Schmitz, Petersen-Mahrt SK, 5-Methylcytosine DNA. demethylation: more than losing a methyl group, Annu Rev Genet, vol.46, pp.419-460, 2012.

N. Bhutani, J. J. Brady, M. Damian, A. Sacco, S. Y. Corbel et al., Reprogramming towards pluripotency requires AID-dependent DNA demethylation, Nature, vol.463, pp.1042-1049, 2010.

Y. F. He, B. Z. Li, Z. Li, P. Liu, Y. Wang et al., Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA, Science, vol.333, pp.1303-1310, 2011.

A. R. Weber, C. Krawczyk, A. B. Robertson, A. Kusnierczyk, C. B. Vagbo et al., Biochemical reconstitution of TET1-TDG-BER-dependent active DNA demethylation reveals a highly coordinated mechanism, Nat Commun, vol.7, p.10806, 2016.

W. G. Kaelin and S. L. Mcknight, Influence of metabolism on epigenetics and disease, Cell, vol.153, issue.1, pp.56-69, 2013.

K. D. Rasmussen and K. Helin, Role of TET enzymes in DNA methylation, development, and cancer, Genes Dev, vol.30, pp.733-50, 2016.

M. Ko, J. An, H. S. Bandukwala, L. Chavez, T. Aijo et al., Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX, Nature, vol.497, pp.122-128, 2013.

G. Chua, K. L. Wassarman, H. Sun, J. A. Alp, E. I. Jarczyk et al., Cytosine-based TET enzyme inhibitors, ACS Med Chem Lett, vol.10, pp.180-185, 2019.

T. Hohenauer and A. W. Moore, The Prdm family: expanding roles in stem cells and development, Development, vol.139, pp.2267-82, 2012.

B. Xiao, J. R. Wilson, and S. J. Gamblin, SET domains and histone methylation, Curr Opin Struct Biol, vol.13, pp.699-705, 2003.

S. Mzoughi, Y. X. Tan, D. Low, and E. Guccione, The role of PRDMs in cancer: one family, two sides, Curr Opin Genet Dev, vol.36, pp.83-91, 2016.

C. Y. Wang and P. Filippakopoulos, Beating the odds: BETs in disease, Trends Biochem Sci, vol.40, pp.468-79, 2015.

T. Fujisawa and F. , Functions of bromodomain-containing proteins and their roles in homeostasis and cancer, Nat Rev Mol Cell Biol, vol.18, pp.246-62, 2017.

Q. Wu, D. Heidenreich, S. Zhou, S. Ackloo, A. Kramer et al., A chemical toolbox for the study of bromodomains and epigenetic signaling, Nat Commun, vol.10, 1915.

C. Mio, S. Bulotta, D. Russo, and G. Damante, Reading cancer Chromatin readers as druggable targets for cancer treatment, Cancers (Basel), vol.11, p.61, 2019.

P. A. Defossez and I. Stancheva, Biological functions of methyl-CpG-binding proteins, Prog Mol Biol Transl Sci, vol.101, pp.377-98, 2011.

A. Bird, The methyl-CpG-binding protein MeCP2 and neurological disease, Biochem Soc Trans, vol.36, pp.575-83, 2008.

G. D. Ginder and D. C. Williams, Readers of DNA methylation, the MBD family as potential therapeutic targets, Pharmacol Ther, vol.184, pp.98-111, 2018.

M. Perez-salvia and M. Esteller, Bromodomain inhibitors and cancer therapy: from structures to applications, Epigenetics, vol.12, pp.323-362, 2017.

A. Ganesan, Multitarget drugs: an epigenetic epiphany, ChemMedChem, vol.11, pp.1227-1268, 2016.

S. Lascano, M. Lopez, and P. B. Arimondo, Natural products and chemical biology tools: alternatives to target epigenetic mechanisms in cancers, Chemical Rec, vol.18, pp.1854-76, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02383679

A. R. De-lera and A. Ganesan, Epigenetic polypharmacology: from combination therapy to multitargeted drugs, Clin Epigenetics, vol.8, p.105, 2016.

L. Morera, M. Lubbert, and M. Jung, Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy, Clin Epigenetics, vol.8, p.57, 2016.

T. E. Mcallister, K. S. England, R. J. Hopkinson, P. E. Brennan, A. Kawamura et al., Recent progress in histone demethylase inhibitors, J Med Chem, vol.59, pp.1308-1337, 2016.

. Références,

S. Jonas and E. Izaurralde, Towards a molecular understanding of microRNAmediated gene silencing, Nat Rev Genet, vol.16, pp.421-454, 2015.

L. Gebert and I. J. Macrae, Regulation of microRNA function in animals, Nat Rev Mol Cell Biol, vol.20, pp.21-37, 2019.

S. Jalvy-delvaille, M. Maurel, V. Majo, N. Pierre, S. Chabas et al., Molecular basis of differential target regulation by miR-96 and miR-182: the Glypican-3 as a model, Nucleic Acids Res, vol.40, pp.1356-65, 2012.

A. Kozomara, M. Birgaoanu, S. Griffiths-jones, and . Mirbase, from microRNA sequences to function, Nucleic Acids Res, vol.47, pp.155-62, 2019.

N. Pinzon, B. Li, L. Martinez, A. Sergeeva, J. Presumey et al.,

, Genome Res, vol.27, pp.234-279, 2017.

E. Indersie, S. Lesjean, K. B. Hooks, F. Sagliocco, T. Ernault et al., MicroRNA therapy inhibits hepatoblastoma growth in vivo by targeting beta-catenin and Wnt signaling, Hepatol Commun, vol.1, pp.168-83, 2017.

F. Cartier, E. Indersie, S. Lesjean, J. Charpentier, K. B. Hooks et al., New tumor suppressor microRNAs target glypican-3 in human liver cancer, Oncotarget, vol.8, pp.41211-41237, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01677287

G. A. Calin, C. D. Dumitru, M. Shimizu, R. Bichi, S. Zupo et al., Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proc Natl Acad Sci, vol.99, pp.15524-15553, 2002.

M. S. Beg, A. J. Brenner, J. Sachdev, M. Borad, Y. K. Kang et al., Phase I. study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors, Invest New Drugs, vol.35, pp.180-188, 2017.

N. Van-zandwijk, N. Pavlakis, S. C. Kao, A. Linton, M. J. Boyer et al., Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study, Lancet Oncol, vol.18, pp.1386-96, 2017.